Determination of Pt in biological fluids with ICP-MS: Evaluation of analytical uncertainty

M. Bettinelli, S. Spezia, A. Ronchi, C. Minoia

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Estimation of the uncertainty associated with analytical methods is necessary in order to establish comparability of the results. Methods of Pt determination in biological fluids very often lack of information about the uncertainty of results. This has implications when results are used to interpret the mechanism of platinum compounds, or when the results are considered to optimize clinical therapies. An ICP-MS method for the determination of Pt in biological fluids (plasma, ultrafiltrate, and urine) of patients treated with antitumor agents has been developed and validated. The limits of quantification (LOQ) in the three matrices were 1.0, 0.1, and 2.0 μg L-1, respectively. Intra-day and inter-day precision and accuracy were in good agreement with the FDA criteria for validation of the analytical methods. The validation study was implemented by assessing the uncertainty evaluation for Pt determination in the different matrices according to the EURACHEM/CITAC Guide.

Original languageEnglish
Pages (from-to)103-111
Number of pages9
JournalAtomic Spectroscopy
Volume25
Issue number3
Publication statusPublished - May 2004

Fingerprint

Fluids
Platinum Compounds
Antineoplastic Agents
Plasmas
Uncertainty

ASJC Scopus subject areas

  • Spectroscopy

Cite this

Determination of Pt in biological fluids with ICP-MS : Evaluation of analytical uncertainty. / Bettinelli, M.; Spezia, S.; Ronchi, A.; Minoia, C.

In: Atomic Spectroscopy, Vol. 25, No. 3, 05.2004, p. 103-111.

Research output: Contribution to journalArticle

Bettinelli, M. ; Spezia, S. ; Ronchi, A. ; Minoia, C. / Determination of Pt in biological fluids with ICP-MS : Evaluation of analytical uncertainty. In: Atomic Spectroscopy. 2004 ; Vol. 25, No. 3. pp. 103-111.
@article{e2c5a81aedf142f5be10dbefb0723829,
title = "Determination of Pt in biological fluids with ICP-MS: Evaluation of analytical uncertainty",
abstract = "Estimation of the uncertainty associated with analytical methods is necessary in order to establish comparability of the results. Methods of Pt determination in biological fluids very often lack of information about the uncertainty of results. This has implications when results are used to interpret the mechanism of platinum compounds, or when the results are considered to optimize clinical therapies. An ICP-MS method for the determination of Pt in biological fluids (plasma, ultrafiltrate, and urine) of patients treated with antitumor agents has been developed and validated. The limits of quantification (LOQ) in the three matrices were 1.0, 0.1, and 2.0 μg L-1, respectively. Intra-day and inter-day precision and accuracy were in good agreement with the FDA criteria for validation of the analytical methods. The validation study was implemented by assessing the uncertainty evaluation for Pt determination in the different matrices according to the EURACHEM/CITAC Guide.",
author = "M. Bettinelli and S. Spezia and A. Ronchi and C. Minoia",
year = "2004",
month = "5",
language = "English",
volume = "25",
pages = "103--111",
journal = "Atomic Spectroscopy",
issn = "0195-5373",
publisher = "Perkin - Elmer Corp.",
number = "3",

}

TY - JOUR

T1 - Determination of Pt in biological fluids with ICP-MS

T2 - Evaluation of analytical uncertainty

AU - Bettinelli, M.

AU - Spezia, S.

AU - Ronchi, A.

AU - Minoia, C.

PY - 2004/5

Y1 - 2004/5

N2 - Estimation of the uncertainty associated with analytical methods is necessary in order to establish comparability of the results. Methods of Pt determination in biological fluids very often lack of information about the uncertainty of results. This has implications when results are used to interpret the mechanism of platinum compounds, or when the results are considered to optimize clinical therapies. An ICP-MS method for the determination of Pt in biological fluids (plasma, ultrafiltrate, and urine) of patients treated with antitumor agents has been developed and validated. The limits of quantification (LOQ) in the three matrices were 1.0, 0.1, and 2.0 μg L-1, respectively. Intra-day and inter-day precision and accuracy were in good agreement with the FDA criteria for validation of the analytical methods. The validation study was implemented by assessing the uncertainty evaluation for Pt determination in the different matrices according to the EURACHEM/CITAC Guide.

AB - Estimation of the uncertainty associated with analytical methods is necessary in order to establish comparability of the results. Methods of Pt determination in biological fluids very often lack of information about the uncertainty of results. This has implications when results are used to interpret the mechanism of platinum compounds, or when the results are considered to optimize clinical therapies. An ICP-MS method for the determination of Pt in biological fluids (plasma, ultrafiltrate, and urine) of patients treated with antitumor agents has been developed and validated. The limits of quantification (LOQ) in the three matrices were 1.0, 0.1, and 2.0 μg L-1, respectively. Intra-day and inter-day precision and accuracy were in good agreement with the FDA criteria for validation of the analytical methods. The validation study was implemented by assessing the uncertainty evaluation for Pt determination in the different matrices according to the EURACHEM/CITAC Guide.

UR - http://www.scopus.com/inward/record.url?scp=3242762908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242762908&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:3242762908

VL - 25

SP - 103

EP - 111

JO - Atomic Spectroscopy

JF - Atomic Spectroscopy

SN - 0195-5373

IS - 3

ER -